https://www.selleckchem.com/pr....oducts/LY2784544.htm
Review Manager Software 5.3 will be used for meta-analysis. The Cochrane risk of bias tool will be used to assess the risk of bias. This study will provide a systematic synthesis of current published data to summarize the effect of trimetazidine on incidence of MACE such as stent restenosis, stent thrombosis, new significant coronary stenosis, myocardial infarction, heart failure, and cardiac arrest in CAD patients undergoing PCI. This meta-analysis will provide evidence as to whether trimetazidine can reduce incidence of MACE in CAD
Like
Comment
Share
